ZYXI Stock Overview
Designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Zynex, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.47 |
| 52 Week High | US$13.77 |
| 52 Week Low | US$6.88 |
| Beta | 0.49 |
| 1 Month Change | -6.01% |
| 3 Month Change | -18.77% |
| 1 Year Change | 9.63% |
| 3 Year Change | -20.85% |
| 5 Year Change | 55.64% |
| Change since IPO | 390.09% |
Recent News & Updates
Recent updates
Earnings Update: Here's Why Analysts Just Lifted Their Zynex, Inc. (NASDAQ:ZYXI) Price Target To US$19.88
May 03
Earnings Miss: Zynex, Inc. Missed EPS By 33% And Analysts Are Revising Their Forecasts
Mar 03Why Investors Shouldn't Be Surprised By Zynex, Inc.'s (NASDAQ:ZYXI) P/E
Jan 24Is Zynex (NASDAQ:ZYXI) Using Too Much Debt?
Aug 03Are Investors Undervaluing Zynex, Inc. (NASDAQ:ZYXI) By 43%?
Mar 30Should You Be Adding Zynex (NASDAQ:ZYXI) To Your Watchlist Today?
Jan 23Short Squeeze Candidate With Low PEG Ratio: Zynex
Oct 05Zynex begins enrollment in blood loss detection trial for CM-1600 monitoring system
Sep 21These 4 Measures Indicate That Zynex (NASDAQ:ZYXI) Is Using Debt Safely
Aug 02Zynex Cures The Pain Of Its Shareholders: Q2 Results
Aug 01Zynex: Upside Looks Well Priced In, Efficiency Headwinds Remain
Jul 25Is Zynex, Inc. (NASDAQ:ZYXI) Trading At A 46% Discount?
Jul 12Zynex June and Q2 orders hit all-time high, re-affirms Q2 and FY22 guidance
Jul 11Is It Time To Consider Buying Zynex, Inc. (NASDAQ:ZYXI)?
Apr 13Zynex (NASDAQ:ZYXI) Seems To Use Debt Quite Sensibly
Mar 23Zynex: Letter Indicates UnitedHealthcare Is Terminating Contract - An Undisclosed Loss Accounting For 50%+ EBITDA
Feb 17Shareholder Returns
| ZYXI | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -4.9% | 1.1% | 1.2% |
| 1Y | 9.6% | 4.2% | 27.7% |
Return vs Industry: ZYXI exceeded the US Medical Equipment industry which returned 4.2% over the past year.
Return vs Market: ZYXI underperformed the US Market which returned 27.7% over the past year.
Price Volatility
| ZYXI volatility | |
|---|---|
| ZYXI Average Weekly Movement | 5.9% |
| Medical Equipment Industry Average Movement | 8.3% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: ZYXI's share price has been volatile over the past 3 months.
Volatility Over Time: ZYXI's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 1,100 | Thomas Sandgaard | www.zynex.com |
Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products.
Zynex, Inc. Fundamentals Summary
| ZYXI fundamental statistics | |
|---|---|
| Market cap | US$336.18m |
| Earnings (TTM) | US$8.17m |
| Revenue (TTM) | US$188.68m |
40.7x
P/E Ratio1.8x
P/S RatioIs ZYXI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZYXI income statement (TTM) | |
|---|---|
| Revenue | US$188.68m |
| Cost of Revenue | US$38.06m |
| Gross Profit | US$150.63m |
| Other Expenses | US$142.46m |
| Earnings | US$8.17m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.26 |
| Gross Margin | 79.83% |
| Net Profit Margin | 4.33% |
| Debt/Equity Ratio | 174.7% |
How did ZYXI perform over the long term?
See historical performance and comparison